2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System

There are no established standards for treatment of neurosarcoidosis. Currently, the first-line standard of care is glucocorticosteroids, “despite the lack of conclusive data,” Dr. Sweiss advised. “DMARDs and TNF inhibitors are safe and effective, but remain investigational.”

Kathy L. Holliman, MEd, is a medical writer based in Beverly, Mass.

References

Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92(2):282–288.
Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336–346.

Neurosarcoidosis & sarcoid dermatopathology are discussed.

Identifying and treating cardiac involvement in systemic sclerosis can be a challenge

COVID-19 causes myriad cardiac dysfunctions, ranging from mild to fulminant disease, including myocarditis, acute congestive heart failure, cardiogenic shock and sudden cardiac death.1,2 COVID-19 myocarditis can mimic cardiac sarcoidosis clinically and on cardiac imaging, which can lead to diagnostic challenges and treatment delays. We present a case of cardiac sarcoidosis with interval development of metabolic…

An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

References

Update on Extrapulmonary Sarcoidosis

The Heart-SCC Puzzle

Case Report: Is It Cardiac Sarcoidosis or COVID-19 Myocarditis?

Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

References

Related Articles